Fuso Pharmaceutical Industries,Ltd. (TYO:4538)
Japan
· Delayed Price · Currency is JPY 2,467.00
-33.00 (-1.32%)
At close: Mar 9, 2026
TYO:4538 Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2013 | FY 2012 | FY 2011 | 2010 - 2006 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '13 Mar 31, 2013 | Mar '12 Mar 31, 2012 | Mar '11 Mar 31, 2011 | 2010 - 2006 |
| Operating Revenue | 62,168 | 60,562 | 55,406 | 48,612 | 44,358 | 47,469 | Upgrade
|
| Other Revenue | 1 | 1 | 1 | - | - | - | Upgrade
|
| Revenue | 62,169 | 60,563 | 55,407 | 48,612 | 44,358 | 47,469 | Upgrade
|
| Revenue Growth (YoY) | 12.20% | 9.31% | 13.98% | 9.59% | -6.55% | 1.95% | Upgrade
|
| Cost of Revenue | 45,764 | 44,030 | 41,567 | 33,296 | 32,164 | 33,659 | Upgrade
|
| Gross Profit | 16,405 | 16,533 | 13,840 | 15,316 | 12,194 | 13,810 | Upgrade
|
| Selling, General & Admin | 13,539 | 12,401 | 11,874 | 9,606 | 9,731 | 9,487 | Upgrade
|
| Research & Development | - | - | - | 1,673 | 1,739 | 1,907 | Upgrade
|
| Operating Expenses | 13,539 | 12,401 | 11,874 | 11,499 | 11,713 | 11,639 | Upgrade
|
| Operating Income | 2,866 | 4,132 | 1,966 | 3,817 | 481 | 2,171 | Upgrade
|
| Interest Expense | -276 | -161 | -171 | -263 | -262 | -306 | Upgrade
|
| Interest & Investment Income | 143 | 107 | 96 | 267 | 56 | 56 | Upgrade
|
| Other Non Operating Income (Expenses) | -161 | -381 | -104 | -57 | -201 | -279 | Upgrade
|
| EBT Excluding Unusual Items | 2,572 | 3,697 | 1,787 | 3,764 | 74 | 1,642 | Upgrade
|
| Gain (Loss) on Sale of Investments | 91 | - | -80 | - | - | -11 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 2,841 | - | -329 | Upgrade
|
| Asset Writedown | - | -7 | -20 | -369 | -67 | -100 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | -218 | Upgrade
|
| Pretax Income | 2,746 | 3,774 | 1,767 | 6,236 | 7 | 984 | Upgrade
|
| Income Tax Expense | 684 | 994 | 390 | 1,365 | -365 | -160 | Upgrade
|
| Net Income | 2,062 | 2,780 | 1,377 | 4,871 | 372 | 1,144 | Upgrade
|
| Net Income to Common | 2,062 | 2,780 | 1,377 | 4,871 | 372 | 1,144 | Upgrade
|
| Net Income Growth | 49.75% | 101.89% | -71.73% | 1209.41% | -67.48% | 120.85% | Upgrade
|
| Shares Outstanding (Basic) | 9 | 9 | 9 | 9 | 9 | 9 | Upgrade
|
| Shares Outstanding (Diluted) | 9 | 9 | 9 | 9 | 9 | 9 | Upgrade
|
| Shares Change (YoY) | -0.83% | -0.79% | -4.89% | -0.02% | -0.03% | -0.03% | Upgrade
|
| EPS (Basic) | 241.47 | 325.43 | 159.92 | 538.01 | 41.08 | 126.30 | Upgrade
|
| EPS (Diluted) | 241.47 | 325.43 | 159.92 | 538.01 | 41.08 | 126.30 | Upgrade
|
| EPS Growth | 50.99% | 103.50% | -70.28% | 1209.63% | -67.47% | 120.91% | Upgrade
|
| Free Cash Flow | - | - | - | 1,330 | -322 | 5,929 | Upgrade
|
| Free Cash Flow Per Share | - | - | - | 146.90 | -35.56 | 654.59 | Upgrade
|
| Dividend Per Share | 87.000 | 82.000 | 70.000 | 60.000 | 60.000 | 60.000 | Upgrade
|
| Dividend Growth | 24.29% | 17.14% | 16.67% | - | - | - | Upgrade
|
| Gross Margin | 26.39% | 27.30% | 24.98% | 31.51% | 27.49% | 29.09% | Upgrade
|
| Operating Margin | 4.61% | 6.82% | 3.55% | 7.85% | 1.08% | 4.57% | Upgrade
|
| Profit Margin | 3.32% | 4.59% | 2.48% | 10.02% | 0.84% | 2.41% | Upgrade
|
| Free Cash Flow Margin | - | - | - | 2.74% | -0.73% | 12.49% | Upgrade
|
| EBITDA | - | - | - | 5,567 | 2,369 | 4,259 | Upgrade
|
| EBITDA Margin | - | - | - | 11.45% | 5.34% | 8.97% | Upgrade
|
| D&A For EBITDA | - | - | - | 1,750 | 1,888 | 2,088 | Upgrade
|
| EBIT | 2,866 | 4,132 | 1,966 | 3,817 | 481 | 2,171 | Upgrade
|
| EBIT Margin | 4.61% | 6.82% | 3.55% | 7.85% | 1.08% | 4.57% | Upgrade
|
| Effective Tax Rate | 24.91% | 26.34% | 22.07% | 21.89% | - | - | Upgrade
|
| Revenue as Reported | 60,563 | 60,563 | 55,407 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.